LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (˜Engitix™), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human...
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Engitix Ltd (˜Engitix™), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary...
Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
LONDON--(BUSINESS WIRE)--Engitix Ltd (‘Engitix’), a biopharmaceutical company with a pioneering and proprietary human extracellular matrix (ECM) drug target discovery platform today announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A (“Dompé”).
Engitix and Takeda are teaming up to develop first-in-class therapies for advanced fibrotic liver diseases using the former’s proprietary ECM discovery platform. How could this partnership transform treatment for these at-need patients?
UK-based biotechnology firm Engitix has signed a licensing and collaboration agreement with Takeda Pharmaceutical for the discovery and development of new drugs to treat fibrotic liver diseases.
LONDON--(BUSINESS WIRE)--Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company Limited (‘Takeda’) to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).